NEW YORK (GenomeWeb News) – Becton Dickinson announced today that it has acquired Sirigen, a maker of polymer dyes that are used in flow cytometry and other technologies.
Hampshire, UK-based Sirigen has developed the High Sensitivity Fluorescence detection technology with applications in the diagnostics and life science research markets. The firm's technology is platform agnostic, and according to its website, can facilitate high-volume screening for personalized medicine purposes and can be used to boost the performance of existing molecular diagnostics tests and immunoassays.
Financial terms of the deal were not disclosed. BD said that it expects the acquisition to be dilutive to its full-year 2012 earnings per share by approximately $.01 on a GAAP basis.
"This new technology is a natural complement to our instrument platforms and reagent portfolio," Alberto Mas, president of the BD Biosciences segment of BD, said in a statement. "We believe that the acquisition will enable us to develop a continuous cadence of novel, unique dyes and antibody specificity releases over the next two years, significantly expanding our life science research reagent portfolio with high-impact products."